Ilumya
(Tildrakizumab)
Provider Summary
Primary Uses
Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Mechanism of action
Monoclonal antibody targeting IL‑23 p19 subunit, reducing downstream inflammatory pathways.
Pre-treatment / Baseline Requirement
Screen for active infection; TB screening (IGRA/PPD) and hepatitis B screening are commonly required for many biologics; baseline CBC and CMP/LFTs are often requested; review vaccination status (avoid live vaccines during therapy per PI); confirm pregnancy status when clinically appropriate; review prior biologic exposure and infection history.
Common side effects
Upper respiratory infection, injection-site reactions, diarrhea.
Serious adverse effects / key risks
Serious infections; hypersensitivity.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
How it works
Targets IL‑23 to reduce inflammation
Before treatment
tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Upper respiratory infection, injection-site reactions, diarrhea.
Get urgent help for
Serious infections; hypersensitivity.
On treatment day
plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.